Home > Publications database > Nanoparticle standards for immuno-based quantitation of α-synuclein oligomers in diagnostics of Parkinson's disease and other synucleopathies > print |
001 | 826558 | ||
005 | 20210129225636.0 | ||
024 | 7 | _ | |a 10.1016/j.cca.2017.01.010 |2 doi |
024 | 7 | _ | |a WOS:000397834600024 |2 WOS |
024 | 7 | _ | |a altmetric:15618115 |2 altmetric |
024 | 7 | _ | |a pmid:28088342 |2 pmid |
037 | _ | _ | |a FZJ-2017-00777 |
082 | _ | _ | |a 540 |
100 | 1 | _ | |a Herrmann, Yvonne |0 P:(DE-Juel1)159122 |b 0 |u fzj |
245 | _ | _ | |a Nanoparticle standards for immuno-based quantitation of α-synuclein oligomers in diagnostics of Parkinson's disease and other synucleopathies |
260 | _ | _ | |a Amsterdam [u.a.] |c 2017 |b Elsevier Science |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1485515224_4643 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
520 | _ | _ | |a Parkinson's disease is a neurodegenerative disorder that is characterized by symptoms such as rigor, tremor and bradykinesia. A reliable and early diagnosis could improve the development of early therapeutic strategies before death of dopaminergic neurons leads to the first clinical symptoms.The sFIDA (surface-based fluorescence intensity distribution analysis) assay is a highly sensitive method to determine the concentration of α-synuclein (α-syn) oligomers, which are presumably the major toxic isoform of α-syn and potentially the most direct biomarker for PD.Oligomer-based diagnostic tests require standard molecules that closely mimic the native oligomer. This is particularly important for calibration and assessment of inter-assay variation. In this study, we generated a standard in form of α-syn coated silica nanoparticles (α-syn-SiNaPs) that are in the size range of α-syn oligomers and provide a defined number of α-syn epitopes.The preparation of the sFIDA assay was realized on an automated platform to allow handling of high number of samples and reduce the effects of human error. The assay outcome was analyzed by determination of coefficient of variation and linearity for the applied α-syn-SiNaPs concentrations. Additionally, the limit of detection and lower limit of quantification were determined yielding concentrations in the lower femtomolar range. |
536 | _ | _ | |a 553 - Physical Basis of Diseases (POF3-553) |0 G:(DE-HGF)POF3-553 |c POF3-553 |f POF III |x 0 |
700 | 1 | _ | |a Bujnicki, Tuyen |0 P:(DE-Juel1)162212 |b 1 |u fzj |
700 | 1 | _ | |a Zafiu, Christian |0 P:(DE-Juel1)162137 |b 2 |u fzj |
700 | 1 | _ | |a Kulawik, Andreas |0 P:(DE-Juel1)162310 |b 3 |u fzj |
700 | 1 | _ | |a Kühbach, Katja |0 P:(DE-Juel1)145440 |b 4 |u fzj |
700 | 1 | _ | |a Peters, Luriano |0 P:(DE-Juel1)145123 |b 5 |u fzj |
700 | 1 | _ | |a Fabig, Judith |0 P:(DE-Juel1)138746 |b 6 |u fzj |
700 | 1 | _ | |a Willbold, Johannes |0 P:(DE-Juel1)159192 |b 7 |u fzj |
700 | 1 | _ | |a Bannach, Oliver |0 P:(DE-Juel1)157832 |b 8 |u fzj |
700 | 1 | _ | |a Willbold, Dieter |0 P:(DE-Juel1)132029 |b 9 |e Corresponding author |u fzj |
773 | _ | _ | |a 10.1016/j.cca.2017.01.010 |0 PERI:(DE-600)1499920-1 |p 152–159 |t Clinica chimica acta |v 466 |y 2017 |x 0009-8981 |
856 | 4 | _ | |u https://juser.fz-juelich.de/record/826558/files/1-s2.0-S0009898117300104-main.pdf |y Restricted |
856 | 4 | _ | |u https://juser.fz-juelich.de/record/826558/files/1-s2.0-S0009898117300104-main.gif?subformat=icon |x icon |y Restricted |
856 | 4 | _ | |u https://juser.fz-juelich.de/record/826558/files/1-s2.0-S0009898117300104-main.jpg?subformat=icon-1440 |x icon-1440 |y Restricted |
856 | 4 | _ | |u https://juser.fz-juelich.de/record/826558/files/1-s2.0-S0009898117300104-main.jpg?subformat=icon-180 |x icon-180 |y Restricted |
856 | 4 | _ | |u https://juser.fz-juelich.de/record/826558/files/1-s2.0-S0009898117300104-main.jpg?subformat=icon-640 |x icon-640 |y Restricted |
909 | C | O | |o oai:juser.fz-juelich.de:826558 |p VDB |
910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)159122 |
910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)162212 |
910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)162137 |
910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)162310 |
910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)145440 |
910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)145123 |
910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 6 |6 P:(DE-Juel1)138746 |
910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 7 |6 P:(DE-Juel1)159192 |
910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 8 |6 P:(DE-Juel1)157832 |
910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 9 |6 P:(DE-Juel1)132029 |
913 | 1 | _ | |a DE-HGF |b Key Technologies |l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences |1 G:(DE-HGF)POF3-550 |0 G:(DE-HGF)POF3-553 |2 G:(DE-HGF)POF3-500 |v Physical Basis of Diseases |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
914 | 1 | _ | |y 2017 |
915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CLIN CHIM ACTA : 2015 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
920 | _ | _ | |l yes |
920 | 1 | _ | |0 I:(DE-Juel1)ICS-6-20110106 |k ICS-6 |l Strukturbiochemie |x 0 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
980 | _ | _ | |a UNRESTRICTED |
981 | _ | _ | |a I:(DE-Juel1)IBI-7-20200312 |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|